Interim 48-month data show 86% of patients with glaucoma or ocular hypertension remain off topical drops after a single cataract procedure, although the drop-free rate has eased from earlier timepoints.
|Articles|February 18, 2021
Blackfin unveils ‘To the Roots’ campaign
Author(s)Brooke Henson, Editor
Eyewear company revisits its origins in new ad campaign
Advertisement
Blackfin eye wear looks back at its origins in a new advertising campaign titled “To the Roots.” Photos set in ethereal landscapes are highlighted alongside glasses and sunglasses of various styles, shapes, and colors.
More at: https://bit. ly/2Mgwgku
Advertisement
Related to this article
CLARITY program data show significantly longer time to treatment failure and higher rates of steroid-free quiescence vs placebo.
Drs Bryce St. Clair and Behrad Garmsiri explain how they build trust, improve health literacy, and destigmatize future interventions for patients with AMD.
Diana Canto-Sims, OD, introduces the second guest of Season 2, Raphael Rostenne, who will be discussing AI-assisted front desk management.
Duravyu gained 2.5 letters vs 6.1 with aflibercept at week 52/56, missing noninferiority in a second phase 3 wet AMD trial.
Alcon's Brytly eye drops received FDA approval for OTC temporary relief of minor ocular redness.
From dry eye to GLP-1s, this year's conference brought a variety of insights from key experts in optometry.
Ryzumvi gained a presbyopia indication in adults based on the phase 3 VEGA-2 and VEGA-3 trials, adding a pharmacologic option for managing near vision loss.
Advertisement
Advertisement
Trending on Optometry Times - Clinical News & Expert Optometrist Insights
1
FDA approves Brytly eye drops for ocular redness relief lasting up to 12 hours
2
More than monitoring: Using AMD visits to promote healthy vision aging
3
Brepocitinib for noninfectious uveitis meets all phase 3 trial end points
4
BIM-IOL System holds 37% IOP reduction at 4 years in first-in-human trial
5